Performance of ALNY Alnylam Pharmaceuticals | -27.5% in 12m
Compare ALNY with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Alnylam Pharmaceuticals with its related Sector/Index XBI
Performance Duell ALNY vs XBI
| TimeFrame | ALNY | XBI |
|---|---|---|
| 1 Day | -0.28% | 1.54% |
| 1 Week | -0.76% | 0.80% |
| 1 Month | -5.70% | -9.93% |
| 3 Months | -20.2% | -5.38% |
| 6 Months | -7.93% | 26.18% |
| 12 Months | -27.5% | 5.24% |
| YTD | -26.5% | -7.47% |
| Rel. Perf. 1m | 0.61 | |
| Rel. Perf. 3m | -2.29 | |
| Rel. Perf. 6m | -3.46 | |
| Rel. Perf. 12m | -3.75 |
Is Alnylam Pharmaceuticals a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Alnylam Pharmaceuticals (NASDAQ:ALNY) is currently (April 2024)
not a good stock to buy. It has a ValueRay Fundamental Rating of -25.07 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALNY as of April 2024 is 119.47. This means that ALNY is currently overvalued and has a potential downside of -16.64% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALNY as of April 2024 is 119.47. This means that ALNY is currently overvalued and has a potential downside of -16.64% (Sold with Premium).
Is ALNY a buy, sell or hold?
- Strong Buy: 11
- Buy: 8
- Hold: 9
- Sell: 0
- Strong Sell: 0
Values above 0%: ALNY is performing better - Values below 0%: ALNY is underperforming
Compare ALNY with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.41% | -3.67% | -32.01% | -54.97% |
| US NASDAQ 100 | QQQ | -4.70% | -2.92% | -33.83% | -66.57% |
| US Dow Jones Industrial 30 | DIA | -1.42% | -3.07% | -25.64% | -44.50% |
| German DAX 40 | DBXD | -3.10% | -4.35% | -30.97% | -41.72% |
| UK FTSE 100 | ISFU | -4.27% | -7.25% | -23.66% | -34.96% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -1.67% | -7.02% | -10.41% | -15.66% |
| Hongkong Hang Seng | HSI | -9.47% | -7.68% | -6.22% | -8.98% |
| Japan Nikkei 225 | EXX7 | -0.69% | 2.31% | -25.01% | -45.24% |
| India NIFTY 50 | INDA | -2.69% | -8.77% | -30.37% | -57.65% |
| Brasil Bovespa | EWZ | -3.36% | -3.47% | -15.04% | -49.41% |
ALNY Alnylam Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -1.57% | -4.15% | -35.10% | -71.50% |
| Consumer Discretionary | XLY | -4.38% | -2.17% | -27.23% | -50.83% |
| Consumer Staples | XLP | -2.30% | -5.86% | -21.60% | -29.58% |
| Energy | XLE | -1.57% | -9.16% | -20.31% | -46.03% |
| Financial | XLF | -1.85% | -4.30% | -36.48% | -56.24% |
| Health Care | XLV | -1.49% | -1.71% | -20.57% | -35.46% |
| Industrial | XLI | -2.58% | -4.66% | -35.08% | -55.87% |
| Materials | XLB | -1.39% | -3.72% | -28.59% | -43.76% |
| Real Estate | XLRE | -2.38% | -0.87% | -20.79% | -31.07% |
| Technology | XLK | -4.55% | -1.93% | -33.16% | -65.33% |
| Utilities | XLU | -1.92% | -10.05% | -20.47% | -27.75% |
| Aerospace & Defense | XAR | -3.69% | -3.95% | -27.73% | -49.44% |
| Biotech | XBI | -1.56% | 4.23% | -34.11% | -32.69% |
| Homebuilder | XHB | -4.31% | -0.57% | -56.70% | -82.19% |
| Retail | XRT | -3.64% | -0.99% | -33.71% | -49.82% |
Does Alnylam Pharmaceuticals outperform its market, is ALNY a Sector Leader?
No, over the last 12 months Alnylam Pharmaceuticals (ALNY) made -27.45%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.24%.
Over the last 3 months ALNY made -20.21%, while XBI made -5.38%.
No, over the last 12 months Alnylam Pharmaceuticals (ALNY) made -27.45%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.24%.
Over the last 3 months ALNY made -20.21%, while XBI made -5.38%.
| Period | ALNY | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -5.70% | -9.93% | -2.03% |
| 3 Months | -20.21% | -5.38% | 4.60% |
| 12 Months | -27.45% | 5.24% | 27.52% |